The Europe Antibiotics Market is witnessing steady growth, driven by the increasing prevalence of infectious diseases, an aging population, and advancements in diagnostic capabilities. These factors ...

France's rising debt, fiscal deficits, and sluggish GDP growth weigh on EWQ ETF performance. See why we rate the ETF a sell ...

Novavax said it was eligible to receive royalties in high teens to low twenties percent on Sanofi sales, up to $350 million ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Discover the top 3 undervalued Pharmaceuticals stocks for Wednesday, February 19 based on AAII’s Stock Grades.

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...